Conference Paper: Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitlePhase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
AuthorsLai, CL
Han, KH
Yoon, SK
Um, SH
Yuen, MF
Kim, HS
Kim, HR
Chung, HC
Kim, CR
Hsyu, P
Averett, D
Worland, S
Kim, J
KeywordsMedical sciences
Gastroenterology
Issue Date2006
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
CitationThe 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0168-8278(06)80007-3
AbstractBACKGROUND: LB80380 (also termed ANA380) is a novel antiviral agent that is converted after administration to LB80317, a novel guanosine phosphonate nucleotide analogue that exhibits potent activity against HBV, including in vitro activity against HBV variants resistant to lamivudine. OBJECTIVES: This study investigates the safety and antiviral activity of escalating doses of LB80380 in HBeAg+ patients with lamivudine-resistant HBV. …
DescriptionConference Reports for NATAP (National AIDS Treatment Advocacy Project)
ISSN0168-8278
2011 Impact Factor: 9.264
2011 SCImago Journal Rankings: 0.765
DOIhttp://dx.doi.org/10.1016/S0168-8278(06)80007-3
DC Field
Value
dc.contributor.authorLai, CL
dc.contributor.authorHan, KH
dc.contributor.authorYoon, SK
dc.contributor.authorUm, SH
dc.contributor.authorYuen, MF
dc.contributor.authorKim, HS
dc.contributor.authorKim, HR
dc.contributor.authorChung, HC
dc.contributor.authorKim, CR
dc.contributor.authorHsyu, P
dc.contributor.authorAverett, D
dc.contributor.authorWorland, S
dc.contributor.authorKim, J
dc.date.accessioned2010-09-25T19:47:25Z
dc.date.available2010-09-25T19:47:25Z
dc.date.issued2006
dc.description.abstractBACKGROUND: LB80380 (also termed ANA380) is a novel antiviral agent that is converted after administration to LB80317, a novel guanosine phosphonate nucleotide analogue that exhibits potent activity against HBV, including in vitro activity against HBV variants resistant to lamivudine. OBJECTIVES: This study investigates the safety and antiviral activity of escalating doses of LB80380 in HBeAg+ patients with lamivudine-resistant HBV. …
dc.descriptionConference Reports for NATAP (National AIDS Treatment Advocacy Project)
dc.description.otherThe 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6
dc.identifier.citationThe 41st Meeting of the European Association for the Study of Liver Diseases (EASL), Vienna, Austria, 26-30 April 2006. In Journal of Hepatology, 2006, v. 44 n. suppl. 2, p. S5, abstract no. 6 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0168-8278(06)80007-3
dc.identifier.doihttp://dx.doi.org/10.1016/S0168-8278(06)80007-3
dc.identifier.epageS5
dc.identifier.hkuros129577
dc.identifier.issn0168-8278
2011 Impact Factor: 9.264
2011 SCImago Journal Rankings: 0.765
dc.identifier.issuesuppl. 2
dc.identifier.openurl
dc.identifier.spageS5
dc.identifier.urihttp://hdl.handle.net/10722/101383
dc.identifier.volume44
dc.languageeng
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
dc.publisher.placeNetherlands
dc.relation.ispartofJournal of Hepatology
dc.subjectMedical sciences
dc.subjectGastroenterology
dc.titlePhase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
dc.typeConference_Paper